Welcome to our dedicated page for Mustgrow Biologics news (Ticker: MGROF), a resource for investors and traders seeking the latest updates and insights on Mustgrow Biologics stock.
MustGrow Biologics Corp. reports developments in biological and regenerative agriculture, including mustard-derived biofertility, biostimulant and biocontrol products. News commonly covers commercialization of TerraSante in U.S. agricultural markets, field work for TerraMG in soil-borne disease suppression, and crop nutrition sales through the NexusBioAg Canadian distribution platform.
Company updates also address annual and quarterly financial results, capital raises, inventory and working-capital funding, organic product registrations, patent portfolio activity, and collaborations with agriculture companies outside North America.
MustGrow (OTCQB: MGROF) received agriculture department registrations in Texas, Utah, and Montana, allowing sales of its mustard-derived organic biofertility product TerraSante(TM). These approvals extend TerraSante's availability to 10 U.S. states under Organic OMRI Listed® certification and California's OIM Program.
According to MustGrow, infield grower data indicate TerraSante may improve crop yields, soil health, and nutrient and water use efficiencies by feeding soil microbes with plant proteins and carbohydrates, with no artificial additives or preservatives used in manufacturing.
MustGrow Biologics (OTCQB:MGROF) announced new market awareness and investor relations agreements aimed at increasing visibility, in line with TSX Venture Exchange disclosure rules.
The company engaged Market One Media Group for 12 months for $70,000 and GBC AG for 24 months at EUR 40,000 per year to reach German and European investors.
MustGrow (OTCQB: MGROF) reported audited 2025 results: sales $8.3M (2024: $0.4M), expenses $7.7M (2024: $5.4M) and a net loss $7.3M (2024: $4.9M). TerraSante U.S. sales were $0.6M (+377%) with a 20% gross margin. Cash was $0.9M and inventory $2.0M as of Dec 31, 2025. The company raised $2M in January 2026 and closed its NexusBioAg Canadian distribution division in April 2026 to focus on U.S. TerraSante growth and scaled contract manufacturing.
MustGrow (OTCQB: MGROF) received Georgia Department of Agriculture registration to sell TerraSante™, its mustard-derived organic biofertility product, expanding state approvals to include Georgia alongside California, Florida, Arizona, Idaho, Oregon, and Washington.
The Georgia registration adds organic OMRI-listed certification coverage and targets high-value Georgia crop acres where TerraSante™ is positioned to be marketed.
MustGrow (TSXV: MGRO / OTCQB: MGROF) announced results from a 2-year, ~100-acre Prairie field program showing its mustard-derived biocontrol TerraMG reduced Clubroot inoculum and improved canola root health and yields. Trials showed up to 95% spore reductions in 2024 and yield gains up to 7 bu/acre (≈19%). The company is pursuing registration with Health Canada's Pest Management Regulatory Agency and reports variable 2025 gains (1–2 bu/acre) in drier, lower-disease conditions.
MustGrow (OTCQB: MGROF / TSXV: MGRO) closed a non-brokered private placement of 4,000,000 units at CA$0.50 per unit for gross proceeds of CA$2.0 million. Each Unit includes one common share and one warrant exercisable at CA$0.70 for 60 months. Net proceeds will fund inventory production for TerraSante, agricultural inventory for NexusBioAg distribution, and working capital. Finder compensation included CA$105,000 cash and 210,000 finder warrants exercisable at CA$0.70 for 60 months. The issuance is subject to final TSXV approval and applicable statutory hold periods for finder warrants.
MustGrow (OTCQB: MGROF) announced a non-brokered private placement (the "LIFE Offering") of up to 4,000,000 Units at $0.50 per Unit to raise up to $2,000,000. Each Unit includes one common share and one warrant exercisable at $0.70 for 60 months. Net proceeds are intended for TerraSante inventory production, inventory for NexusBioAg distribution, and working capital. Closing is expected on or about January 22, 2026, subject to TSXV approval and other conditions. Eligible finders may receive up to 6% cash fees and Finder's Warrants representing up to 6% of Shares issued to introduced investors. Insider participation is anticipated and will be subject to TSXV hold periods and MI 61-101 exemptions.
MustGrow (OTCQB: MGROF) issued a CEO letter dated December 18, 2025 describing its 2025 transition from product development to commercialization. Key points: TerraSante saw accelerating U.S. demand with repeat orders after field trials; a Washington grower reported a 2 ton/acre potato yield gain and ~35% more A/B grades, implying ~US$5,000/acre added value versus ~US$180/acre product cost. MustGrow plans 2026 manufacturing scale‑ups with contract manufacturers to improve margins and is pursuing additional production partners and international registrations. TerraMG registration work continues in Canada and the U.S., and Bayer partnership progress in EMEA remains active.
MustGrow (OTCQB: MGROF) reported large-scale U.S. potato field results showing material yield, size and quality gains from its organic TerraSanteTM biofertility product.
Customer data in Washington showed an approximate 2 ton/acre yield increase and larger tuber size with fewer culls, which the farmer estimated as about a US$5,000 increase in value per acre at a product cost of US$180/acre. Small-plot trials also showed yield lifts vs untreated: +27.6% at 15 lbs/ac, +25.8% at 20 lbs/ac, and +39.2% at 50 lbs/ac. TerraSante is OMRI listed and registered for sale in CA, FL, AZ, ID, OR, WA. The company highlights soil-microbiome and nutrient-use benefits when used with grower programs.
MustGrow (OTCQB: MGROF) reported Q3-2025 operating and financial results for the three months ended September 30, 2025, announcing its first recorded quarterly sales since the prior-year period.
- Sales revenue: $0.8 million in Q3-2025 vs. no revenue in Q3-2024
- Gross profit: $180,555; gross margin 22.9% (up from 20.9% in Q2-2025)
- Cash and equivalents: $3.3 million as of September 30, 2025
- Inventory: $1.9 million as of September 30, 2025
The company noted Q3 is a seasonal shoulder period for Canadian agriculture and expects stronger retail demand in Q4-2025 and Q1-2026 as farmers buy crop inputs. Management cited margin improvement driven by higher-margin product sales through NexusBioAg and continues to allocate capital toward NexusBioAg and U.S. TerraSante biofertility sales.